Common Stock, par value $0.001 per share
- Symbol
- CRNX
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Historical · closed Sep 1, 2026
Current Report · Items 2.02, 9.01 · 8-K
Crinetics Pharmaceuticals, Inc.
Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On August 3, 2026, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) issued a press release reporting its financial results for the period ended June 30, 2026. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.…
Press release in this filing
Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results →Company context
Crinetics Pharmaceuticals is a global pharmaceutical company committed to transforming the treatment of endocrine diseases through science rooted in patient needs. Crinetics is focused on discovering, developing, and commercializing novel therapies, with core expertise in targeting G-protein coupled receptors (GPCRs) with small molecules that have specifically tailored pharmacology and properties.
Historical securities (1)
Registered securities in this filing
Crinetics Pharmaceuticals, Inc. · 8-K · Filed 2026-08-03
Disclosure sections
Item 2.02Item 2.02 - Results of Operations
Item 2.02 Results of Operations and Financial Condition.
On August 3, 2026, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) issued a press release reporting its financial results for the period ended June 30, 2026. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
In accordance with General Instruction B.2 of Form 8-K, the information contained or incorporated herein, including the press release furnished as Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such filing to this Current Report on Form 8-K.